Skip to main content
SpringerLink
Log in

Molecular Imaging in Head and Neck Squamous Cell Carcinoma Patients

  • Conference paper
  • First Online:
Critical Issues in Head and Neck Oncology

Abstract

Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at an advanced stage, and despite intensive treatment prognosis remains poor. Accurate staging and tumor delineation are essential for determination of a personalized treatment strategy. Molecular imaging with radionuclides or fluorescent probes allows visualization of tumor biology in vivo. Positron emission tomography (PET) imaging gives whole body information with low resolution whereas optical molecular imaging has a high resolution but limited penetration and limited field of view. Therefore, PET imaging might improve staging and radiotherapy planning and optical imaging is of interest for early detection and guidance of surgical resection in HNSCC. In this chapter we describe how these techniques can be used to study the presence and distribution of specific tumor characteristics and tumor delivery of drugs. In addition, the current role of 18F-fluorodeoxyglucose (18F-FDG) PET is addressed, and non-FDG PET tracers including tracers for hypoxia and epidermal growth factor receptor (EGFR) imaging are discussed. We describe development of EGFR imaging with fluorescence and address preclinical imaging results in HNSCC models for other molecular targets, including integrin αvβ3. Adequately powered clinical trials are needed to assess the added value of molecular imaging before implementation, and standardization of techniques and endpoints is essential.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mankoff DA. A definition of molecular imaging. J Nucl Med. 2007;48:18N, 21N.

    PubMed  Google Scholar 

  2. Chou SW, Shau YH, Wu PC, Yang YS, Shieh DB, Chen CC. In vitro and in vivo studies of FePt nanoparticles for dual modal CT/MRI molecular imaging. J Am Chem Soc. 2010;132:13270–8.

    Article  CAS  PubMed  Google Scholar 

  3. Shi Y, Oeh J, Eastham-Anderson J, Yee S, Finkle D, Peale Jr FV, et al. Mapping in vivo tumor oxygenation within viable tumor by 19F-MRI and multispectral analysis. Neoplasia. 2013;15:1241–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Paefgen V, Doleschel D, Kiessling F. Evolution of contrast agents for ultrasound imaging and ultrasound-mediated drug delivery. Front Pharmacol. 2015;6:197.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Lamberts LE, Williams SP, Terwisscha van Scheltinga AG, Lub-de Hooge MN, Schröder CP, Gietema JA, et al. Antibody positron emission tomography imaging in anticancer drug development. J Clin Oncol. 2015;33:1491–504.

    Article  CAS  PubMed  Google Scholar 

  6. Cammaroto G, Quartuccio N, Sindoni A, Di Mauro F, Caobelli F, Young AIMN Working Group. The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature. Eur Arch Otorhinolaryngol. 2016;273(8):1961–73.

    Article  PubMed  Google Scholar 

  7. Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol. 2012;30:3884–92.

    Article  PubMed  PubMed Central  Google Scholar 

  8. NCCN Guidelines version 1. 2015. www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed 19 Dec 2015.

  9. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol. 2008;33:210–22.

    Article  CAS  PubMed  Google Scholar 

  10. Mehanna H, Wong WL, McConkey CC, Rahman JK, Robinson M, Hartley AG, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med. 2016;374:1444–54.

    Google Scholar 

  11. Xie P, Li M, Zhao H, Sun X, Fu Z, Yu J. 18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis. J Cancer Res Clin Oncol. 2011;137:1085–93.

    Article  PubMed  Google Scholar 

  12. Rasmussen JH, Vogelius IR, Fischer BM, Friborg J, Aznar MC, Persson GF, et al. Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma. Head Neck. 2015;37:1274–81.

    Article  PubMed  Google Scholar 

  13. Differding S, Hanin FX, Grégoire V. PET imaging biomarkers in head and neck cancer. Eur J Nucl Med Mol Imaging. 2015;42:613–22.

    Article  CAS  PubMed  Google Scholar 

  14. Rajendran JG, Schwartz DL, O’Sullivan J, Peterson LM, Ng P, Scharnhorst J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol. 2012;105:14–20.

    Article  PubMed  Google Scholar 

  16. Zegers CM, van Elmpt W, Hoebers FJ, Troost EG, Öllers MC, Mottaghy FM, et al. Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma. Acta Oncol. 2015;54:1378–84.

    Article  CAS  PubMed  Google Scholar 

  17. Komar G, Lehtiö K, Seppänen M, Eskola O, Levola H, Lindholm P, et al. Prognostic value of tumour blood flow, [18F]EF5 and [18F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy. Eur J Nucl Med Mol Imaging. 2014;41:2042–50.

    Article  CAS  PubMed  Google Scholar 

  18. Sato Y, Tsujikawa T, Oh M, Mori T, Kiyono Y, Fujieda S, et al. Assessing tumor hypoxia in head and neck cancer by PET with 62Cu-diacetyl-bis(N 4-methylthiosemicarbazone). Clin Nucl Med. 2014;39:1027–32.

    Article  PubMed  Google Scholar 

  19. Grassi I, Nanni C, Cicoria G, Blasi C, Bunkheila F, Lopci E, et al. Usefulness of 64Cu-ATSM in head and neck cancer: a preliminary prospective Study. Clin Nucl Med. 2014;39:e59–63.

    Article  PubMed  Google Scholar 

  20. Hoeben BA, Troost EG, Span PN, van Herpen CM, Bussink J, Oyen WJ, et al. 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med. 2013;54:532–40.

    Article  CAS  PubMed  Google Scholar 

  21. Ito K, Yokoyama J, Miyata Y, Toyohara J, Okasaki M, Minamimoto R, et al. Volumetric comparison of positron emission tomography/computed tomography using 4′-[methyl-11C]-thiothymidine with 2-deoxy-2-18F-fluoro-D-glucose in patients with advanced head and neck squamous cell carcinoma. Nucl Med Commun. 2015;36:219–25.

    Article  CAS  PubMed  Google Scholar 

  22. Wedman J, Pruim J, Langendijk JA, van der Laan BF. Visualization of small glottic laryngeal cancer using methyl-labeled 11C-methionine positron emission tomography. Oral Oncol. 2009;45:703–5.

    Article  CAS  PubMed  Google Scholar 

  23. Kim M, Achmad A, Higuchi T, Arisaka Y, Yokoo H, Yokoo S, et al. Effects of intratumoral inflammatory process on 18F-FDG uptake: pathologic and comparative study with 18F-fluoro-α-methyltyrosine PET/CT in oral squamous cell carcinoma. J Nucl Med. 2015;56:16–21.

    Article  CAS  PubMed  Google Scholar 

  24. Pauleit D, Zimmermann A, Stoffels G, Bauer D, Risse J, Flüss MO, et al. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med. 2006;47:256–61.

    PubMed  Google Scholar 

  25. Burger IA, Zitzmann-Kolbe S, Pruim J, Friebe M, Graham K, Stephens A, et al. First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86–9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. J Nucl Med. 2014;55:1778–85.

    Article  CAS  PubMed  Google Scholar 

  26. Ito K, Yokoyama J, Kubota K, Morooka M, Shiibashi M, Matsuda H. 18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence. Eur J Nucl Med Mol Imaging. 2010;37:1318–27.

    Article  CAS  PubMed  Google Scholar 

  27. Parashar B, Wernicke AG, Rice S, Osborne J, Singh P, Nori D, et al. Early assessment of radiation response using a novel functional imaging modality -[18F]fluorocholine PET (FCH-PET): a pilot study. Discov Med. 2012;14:13–20.

    PubMed  PubMed Central  Google Scholar 

  28. Schartinger VH, Dudás J, Decristoforo C, Url C, Schnabl J, Göbel G, et al. 68Ga-DOTA0-Tyr3-octreotide positron emission tomography in head and neck squamous cell carcinoma. Med Mol Imaging. 2013;40:1365–72.

    Article  Google Scholar 

  29. Tani H, Kurihara H, Hiroi K, Honda N, Yoshimoto M, Kono Y, et al. Correlation of 18F-BPA and 18F-FDG uptake in head and neck cancers. Radiother Oncol. 2014;113:193–7.

    Article  PubMed  Google Scholar 

  30. Hino-Shishikura A, Suzuki A, Minamimoto R, Shizukuishi K, Oka T, Tateishi U, et al. Biodistribution and radiation dosimetry of [18F]-5-fluorouracil. Appl Radiat Isot. 2013;75:11–7.

    Article  CAS  PubMed  Google Scholar 

  31. Heukelom J, Hamming O, Bartelink H, Hoebers F, Giralt J, Herlestam T, et al. Adaptive and innovative radiation treatment FOR improving cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer. 2013;13:84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Börjesson PK, Jauw YW, de Bree R, Roos JC, Castelijns JA, Leemans CR, et al. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009;50:1828–36.

    Article  PubMed  Google Scholar 

  33. Heuveling DA, de Bree R, Vugts DJ, Huisman MC, Giovannoni L, Hoekstra OS, et al. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. J Nucl Med. 2013;54:397–401.

    Article  CAS  PubMed  Google Scholar 

  34. Lopci E, Grassi I, Chiti A, Nanni C, Cicoria G, Toschi L, et al. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am J Nucl Med Mol Imaging. 2014;4:365–84.

    PubMed  PubMed Central  Google Scholar 

  35. Peeters SG, Zegers CM, Yaromina A, Van Elmpt W, Dubois L, Lambin P. Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles. Q J Nucl Med Mol Imaging. 2015;59:39–57.

    CAS  PubMed  Google Scholar 

  36. Rajendran JG, Krohn KA. F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy. Semin Nucl Med. 2015;45:151–62.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Thorwarth D, Eschmann SM, Scheiderbauer J, Paulsen F, Alber M. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer. 2005;5:152.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006;24:2098–104.

    Article  PubMed  Google Scholar 

  39. Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M, et al. Hypoxia-imaging with 18F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol. 2007;83:406–10.

    Article  CAS  PubMed  Google Scholar 

  40. Nehmeh SA, Lee NY, Schröder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:235–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with 18F-FDG PET, 18F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med. 2009;50:1020–7.

    Article  PubMed  Google Scholar 

  42. Lee N, Nehmeh S, Schöder H, Fury M, Chan K, Ling CC, et al. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;75:101–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Bittner MI, Wiedenmann N, Bucher S, Hentschel M, Mix M, Weber WA, et al. Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy. Radiother Oncol. 2013;108:511–6.

    Article  PubMed  Google Scholar 

  44. Kikuchi M, Yamane T, Shinohara S, Fujiwara K, Hori SY, Tona Y, et al. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann Nucl Med. 2011;25:625–33.

    Article  CAS  PubMed  Google Scholar 

  45. Yamane T, Kikuchi M, Shinohara S, Senda M. Reduction of [18F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma. Mol Imaging Biol. 2011;13:227–31.

    Article  PubMed  Google Scholar 

  46. Zips D, Zöphel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol. 2012;105:21–8.

    Article  PubMed  Google Scholar 

  47. Henriques de Figueiredo B, Merlin T, de Clermont-Gallerande H, Hatt M, Vimont D, Fernandez P, et al. Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas. Strahlenther Onkol. 2013;189:1015–9.

    Article  CAS  PubMed  Google Scholar 

  48. Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med. 2013;54:201–7.

    Article  CAS  PubMed  Google Scholar 

  49. Sato J, Kitagawa Y, Yamazaki Y, Hata H, Asaka T, Miyakoshi M, et al. Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:2031–41.

    Article  CAS  PubMed  Google Scholar 

  50. Wiedenmann NE, Bucher S, Hentschel M, Mix M, Vach W, Bittner MI, et al. Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome. Radiother Oncol. 2015;117:113–7.

    Article  PubMed  Google Scholar 

  51. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer. 2008;44:946–53.

    Article  CAS  PubMed  Google Scholar 

  52. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst. 2010;102:152–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Lin Z, Mechalakos J, Nehmeh S, Schoder H, Lee N, Humm J, et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys. 2008;70:1219–28.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2008;70:2–13.

    Article  CAS  PubMed  Google Scholar 

  55. Choi W, Lee SW, Park SH, Ryu JS, Oh SJ, Im KC, et al. Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer. Radiother Oncol. 2010;97:176–82.

    Article  PubMed  Google Scholar 

  56. Toma-Dasu I, Uhrdin J, Antonovic L, Dasu A, Nuyts S, Dirix P, et al. Dose prescription and treatment planning based on FMISO-PET hypoxia. Acta Oncol. 2012;51:222–30.

    Article  PubMed  Google Scholar 

  57. Henriques de Figueiredo B, Zacharatou C, Galland-Girodet S, Benech J, De Clermont-Gallerande H, Lamare F, et al. Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers. Strahlenther Onkol. 2015;191:217–24.

    Article  CAS  PubMed  Google Scholar 

  58. Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol. 2012;30:1777–83.

    Article  CAS  PubMed  Google Scholar 

  59. Rischin D, Peters LJ, O’Sullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010;28:2989–95.

    Article  CAS  PubMed  Google Scholar 

  60. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5–85. Radiother Oncol. 1998;46:135–46.

    Article  CAS  PubMed  Google Scholar 

  61. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.

    Article  CAS  PubMed  Google Scholar 

  62. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.

    Article  CAS  PubMed  Google Scholar 

  63. Zhang L, Castanaro C, Luan B, Yang K, Fan L, Fairhurst JL, et al. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. Mol Cancer Ther. 2014;13:1345–55.

    Article  CAS  PubMed  Google Scholar 

  64. Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res. 2013;73:824–33.

    Article  CAS  PubMed  Google Scholar 

  65. Licitra L, Störkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer. 2013;49:1161–8.

    Article  CAS  PubMed  Google Scholar 

  66. Chauhan VP, Stylianopoulos T, Martin JD, Popović Z, Chen O, Kamoun WS, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol. 2012;7:383–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Arjaans M, Schröder CP, Oosting SF, Dafni U, Kleibeuker JE, de Vries EG. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget. 2016. doi:10.18632/oncotarget.6918. [Epub ahead of print].

    PubMed  PubMed Central  Google Scholar 

  68. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging. 2007;34:850–8.

    Article  CAS  PubMed  Google Scholar 

  69. Ping Li W, Meyer LA, Capretto DA, Sherman CD, Anderson CJ. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm. 2008;23:158–71.

    Article  PubMed  Google Scholar 

  70. Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009;50:123–31.

    Article  CAS  PubMed  Google Scholar 

  71. van Dijk LK, Boerman OC, Kaanders JH, Bussink J. PET imaging in head and neck cancer patients to monitor treatment response: a future role for EGFR-targeted imaging. Clin Cancer Res. 2015;21:3602–9.

    Article  PubMed  CAS  Google Scholar 

  72. van Dijk LK, Hoeben BA, Stegeman H, Kaanders JH, Franssen GM, Boerman OC, et al. 111In-cetuximab-F(ab’)2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts. Radiother Oncol. 2013;108:484–8.

    Article  PubMed  CAS  Google Scholar 

  73. van Dijk LK, Yim CB, Franssen GM, Kaanders JH, Rajander J, Solin O, et al. PET of EGFR with (64) Cu-cetuximab-F(ab’)2 in mice with head and neck squamous cell carcinoma xenografts. Contrast Media Mol Imaging. 2016;11:65–70.

    Article  PubMed  CAS  Google Scholar 

  74. van Dijk LK, Boerman OC, Franssen GM, Lok J, Kaanders JH, Bussink J. Early response monitoring with 18F-FDG PET and cetuximab-F(ab’)2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model. J Nucl Med. 2014;55:1665–70.

    Article  PubMed  CAS  Google Scholar 

  75. van Dijk LK, Boerman OC, Franssen GM, Kaanders JH, Bussink J. 111In-cetuximab-F(ab’)2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model. J Nucl Med. 2015;56:287–92.

    Article  PubMed  CAS  Google Scholar 

  76. Makris NE, Boellaard R, van Lingen A, Lammertsma AA, van Dongen GA, Verheul HM, et al. PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab. J Nucl Med. 2015;56:249–54.

    Article  CAS  PubMed  Google Scholar 

  77. Terwisscha van Scheltinga AG, Lub-de Hooge MN, Abiraj K, Schröder CP, Pot L, Bossenmaier B, et al. ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody 89Zr-RG7116. MAbs. 2014;6:1051–8.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Lockhart AC, Liu Y, Dehdashti F, Laforest R, Picus J, Frye J, et al. Phase 1 evaluation of [64Cu]DOTA-patritumab to assess dosimetry, apparent receptor occupancy, and safety in subjects with advanced solid tumors. Mol Imaging Biol. 2015;18(3):446–53.

    Article  CAS  Google Scholar 

  79. Bensch F, Lamberts, LE, Lub-de Hooge MN, Terwisscha van Scheltinga AG, de Jong JR, Gietema JA, et al. Phase I imaging study of the HER3 antibody RG7116 using 89Zr-RG7116 PET in patients with metastatic or locally advanced HER 3 positive solid tumors. J Clin Oncol. 2014;32 Suppl 15. abstract 11095.

    Google Scholar 

  80. Segal NH, Ou SI, Balmanoukian AS, Fury MG, Massarelli E, Brahmer JR, et al. Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. J Clin Oncol. 2015;33 Suppl 15. abstract 3011.

    Google Scholar 

  81. Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the KEYNOTE-012 expansion cohort. J Clin Oncol. 2016; Sep 19. pii: JCO681478. [Epub ahead of print]

    Google Scholar 

  82. Heskamp S, Hobo W, Molkenboer-Kuenen JD, Olive D, Oyen WJ, Dolstra H, et al. Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies. Cancer Res. 2015;75:2928–36.

    Article  CAS  PubMed  Google Scholar 

  83. Chatterjee S, Lesniak WG, Gabrielson M, Lisok A, Wharram B, Sysa-Shah P, et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget. 2016;7(9):10215–27. doi:10.18632/oncotarget.7143. [Epub ahead of print].

    PubMed  PubMed Central  Google Scholar 

  84. Glaudemans AW, Bonanno E, Galli F, Zeebregts CJ, de Vries EF, Koole M, et al. In vivo and in vitro evidence that 99mTc-HYNIC-interleukin-2 is able to detect T lymphocytes in vulnerable atherosclerotic plaques of the carotid artery. Eur J Nucl Med Mol Imaging. 2014;41:1710–9.

    Article  CAS  PubMed  Google Scholar 

  85. Signore A, Annovazzi A, Barone R, Bonanno E, D’Alessandria C, Chianelli M, et al. 99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study. J Nucl Med. 2004;45:1647–52.

    PubMed  Google Scholar 

  86. Di Gialleonardo V, Signore A, Willemsen AT, Sijbesma JW, Dierckx RA, de Vries EF. Pharmacokinetic modelling of N-(4-[18F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation. Eur J Nucl Med Mol Imaging. 2012;39:1551–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Di Gialleonardo V, Signore A, Glaudemans AW, Dierckx RA, De Vries EF. N-(4-18F-fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes. J Nucl Med. 2012;53:679–86.

    Article  PubMed  CAS  Google Scholar 

  88. Tavaré R, McCracken MN, Zettlitz KA, Knowles SM, Salazar FB, Olafsen T, et al. Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo. Proc Natl Acad Sci U S A. 2014;111:1108–13.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  89. Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev. 2015. doi:10.1016/j.addr.2015.11.009. [Epub ahead of print] Review.

    PubMed  Google Scholar 

  90. Blykers A, Schoonooghe S, Xavier C, D’hoe K, Laoui D, D’Huyvetter M, et al. PET Imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments. J Nucl Med. 2015;56:1265–71.

    Article  CAS  PubMed  Google Scholar 

  91. Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJ, Frangioni JV. Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol. 2013;10:507–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Davies K, Connolly JM, Dockery P, Wheatley AM, Olivo M, Keogh I. Point of care optical diagnostic technologies for the detection of oral and oropharyngeal squamous cell carcinoma. Surgeon. 2015;13:321–9.

    Article  CAS  PubMed  Google Scholar 

  93. Muto M, Minashi K, Yano T, Saito Y, Oda I, Nonaka S, et al. Early detection of superficial squamous cell carcinoma in the head and neck region and esophagus by narrow band imaging: a multicenter randomized controlled trial. J Clin Oncol. 2010;28:1566–72.

    Article  PubMed  PubMed Central  Google Scholar 

  94. de Boer E, Warram JM, Tucker MD, Hartman YE, Moore LS, de Jong JS, et al. In vivo fluorescence immunohistochemistry: localization of fluorescently labeled cetuximab in squamous cell carcinomas. Sci Rep. 2015;5:10169.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  95. Rosenthal EL, Warram JM, de Boer E, Chung TK, Korb ML, Brandwein-Gensler M, et al. Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer. Clin Cancer Res. 2015;21:3658–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Chung TK, Warram J, Day KE, Hartman Y, Rosenthal EL. Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies. Cancer Biol Ther. 2015;16:790–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Yang K, Zhang FJ, Tang H, Zhao C, Cao YA, Lv XQ, et al. In-vivo imaging of oral squamous cell carcinoma by EGFR monoclonal antibody conjugated near-infrared quantum dots in mice. Int J Nanomedicine. 2011;6:1739–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Nitin N, Rosbach KJ, El-Naggar A, Williams M, Gillenwater A, Richards-Kortum RR. Optical molecular imaging of epidermal growth factor receptor expression to improve detection of oral neoplasia. Neoplasia. 2009;11:542–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Atallah I, Milet C, Henry M, Josserand V, Reyt E, Coll JL, et al. Near-infrared fluorescence imaging-guided surgery improves recurrence-free survival rate in novel orthotopic animal model of head and neck squamous cell carcinoma. Head Neck. 2014. doi:10.1002/hed.23980. [Epub ahead of print].

    Google Scholar 

  100. Atallah I, Milet C, Quatre R, Henry M, Reyt E, Coll JL, et al. Role of near-infrared fluorescence imaging in the resection of metastatic lymph nodes in an optimized orthotopic animal model of HNSCC. Eur Ann Otorhinolaryngol Head Neck Dis. 2015;132:337–42.

    Article  CAS  PubMed  Google Scholar 

  101. Huang H, Bai YL, Yang K, Tang H, Wang YW. Optical imaging of head and neck squamous cell carcinoma in vivo using arginine-glycine-aspartic acid peptide conjugated near-infrared quantum dots. Onco Targets Ther. 2013;6:1779–87.

    PubMed  PubMed Central  Google Scholar 

  102. Baeten J, Suresh A, Johnson A, Patel K, Kuriakose M, Flynn A, et al. Molecular imaging of oral premalignant and malignant lesions using fluorescently labeled lectins. Transl Oncol. 2014;7:213–20.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Uddin MJ, Crews BC, Ghebreselasie K, Daniel CK, Kingsley PJ, Xu S, et al. Targeted imaging of cancer by fluorocoxib C, a near-infrared cyclooxygenase-2 probe. J Biomed Opt. 2015;20:50502.

    Article  PubMed  CAS  Google Scholar 

  104. Sun X, Gao D, Gao L, Zhang C, Yu X, Jia B, et al. Molecular imaging of tumor-infiltrating macrophages in a preclinical mouse model of breast cancer. Theranostics. 2015;5:597–608.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Zhang C, Gao L, Cai Y, Liu H, Gao D, Lai J, et al. Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model. Biomaterials. 2016;84:1–12.

    Article  CAS  PubMed  Google Scholar 

  106. Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME, et al. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med. 2007;48:1501–10.

    Article  CAS  PubMed  Google Scholar 

  107. Mukherjee A, Shim Y, Myong SJ. Quantum dot as probe for disease diagnosis and monitoring. Biotechnol J. 2016;11:31–42.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University of Groningen, University Medical Center Groningen, 30 001, 9700 RB, Groningen, The Netherlands

    Sjoukje F. Oosting MD, PhD & Elisabeth G. E. de Vries

  2. Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, 30 001, 9700 RB, Groningen, The Netherlands

    Max J. H. Witjes

Authors
  1. Sjoukje F. Oosting MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisabeth G. E. de Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Max J. H. Witjes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sjoukje F. Oosting MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium

    Jan B. Vermorken

  2. Departments for Radiation Oncology, Charité University Medicine, Berlin, Germany

    Volker Budach

  3. Department of Otolaryngology, VU University Medical Center, Amsterdam, The Netherlands

    C. René Leemans

  4. Department of Medical Oncology, Université catholique de Louvain, Brussels, Belgium

    Jean-Pascal Machiels

  5. Department of Otorhinolarynology, University of Brescia, Brescia, Italy

    Piero Nicolai

  6. Princess Margaret Hospital, Toronto, Canada

    Brian O'Sullivan

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this paper

Cite this paper

Oosting, S.F., de Vries, E.G.E., Witjes, M.J.H. (2017). Molecular Imaging in Head and Neck Squamous Cell Carcinoma Patients. In: Vermorken, J., Budach, V., Leemans, C., Machiels, JP., Nicolai, P., O'Sullivan, B. (eds) Critical Issues in Head and Neck Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42909-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42909-0_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42907-6

  • Online ISBN: 978-3-319-42909-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation